Autophagic vacuolar myopathy (AVM) consists of multiple rare genetic disorders with common histological and pathological features on muscle biopsy.[1] The features highlighted are vacuolar membranes of the autophagic vacuoles having sarcolemmal characteristics and an excess of autophagic vacuoles.[2] There are currently five types of AVM identified.[1] The signs and symptoms become more severe over the course of the disease. It begins with an inability to pick up small objects and progresses to difficulty in walking.[3] The age of onset varies from early childhood to late adulthood, affecting people of all ages.[4]
The disorders are caused by a mutation in different parts of the chromosome: Danon disease is caused by a mutation of the LAMP2 gene; XMEA is caused by mutations of the VMA21 gene.[5] These gene mutations slow down the fusion between autophagic vacuoles and lysosomes, leading to the accumulation of autophagic vacuoles.[5] The result is the breakdown of muscle cells, which attributes to muscle weakness in patients with AVM.[5] The mode of transmission is X-linked, with Danon Disease being X-linked dominant and XMEA being X-linked recessive.[6] Other types of AVM are less researched in terms of their mode of transmission, but it is known that these diseases are all gene-related.[6]
Diagnosis of AVM involves various types of genetic testing, alongside a thorough examination of the patient's history and symptoms.[1] Treatment of the disease currently involves Enzyme Replacement Therapy and gene therapy is a possibility for the future, a solution which may cure the disease completely.[7]
:3
was invoked but never defined (see the help page).